Company intelligence / Profile preview

KWHC

Ownership: Private
Development stage: Other

Overview

KweHealth is pioneering the development of cell-free regenerative therapies based on perinatal-derived exosomes. The company integrates advanced biomanufacturing technologies with AI-driven analytics to ensure product efficacy and safety. No specific clinical results are disclosed as of now; the company appears focused on preclinical research, process innovation, and platform development for future therapeutic applications

Therapeutic areas: Other
Modalities: Exosome-based therapyCell-free therapy
Industry: Biotech

Drug pipeline

5 assets

AVEXO

Preclinical

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on KWHC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KWHC.

Explore the full profile